Based on YouTube archive.
https://www.youtube.com/watch?v=Mfia3ZAuc0c
##
Report: UCLA World Parkinson’s Day Symposium, April 11, 2026
What made the symposium effective was its architecture. It was not just a patient-education morning, and it was not just a research seminar. It was deliberately organized as a walk across the full Parkinson’s pipeline: basic disease mechanisms, protein misfolding, microglial biology, human gait circuitry, preclinical drug development, and finally active clinical trials. The result was a coherent picture of Parkinson’s disease not as a single narrow motor disorder, but as a long, slowly evolving, biologically diverse condition in which neurons, glia, proteins, environmental exposures, aging, and circuitry all interact.
Dr. Zeiger’s opening set the tone by translating technical vocabulary into plain language. He reviewed the basic cast of brain cell types—neurons, oligodendrocytes, astrocytes, and microglia—and emphasized that Parkinson’s cannot be understood only as a problem of dopamine neurons. He explained the familiar anatomy of the substantia nigra, the loss of pigmented dopamine-producing neurons, and the role of alpha-synuclein aggregation in forming Lewy bodies. This introductory section was modest in ambition but very important in function: it gave the audience a shared conceptual language for everything that followed.
The first major scientific lecture, from Dr. Jeff Bronstein, provided the symposium’s clearest statement of the current etiologic model of Parkinson’s disease. Bronstein argued that Parkinson’s is usually not caused by one thing, but by an accumulation of risk factors acting on a susceptible biological background. His framework combined rare high-impact mutations, common low-impact genetic polymorphisms, environmental toxicants, aging, inflammation, mitochondrial stress, and impaired protein-clearance pathways. He repeatedly returned to a central idea: Parkinson’s is likely a disorder that begins years to decades before diagnosis, with nonmotor symptoms such as constipation, smell loss, anxiety, dream-enactment behavior, and autonomic changes appearing well before tremor or bradykinesia.
Bronstein’s talk was also the symposium’s strongest reminder that association is not the same as causation. He reviewed epidemiologic links—smoking, alcohol, coffee, exercise, diet, pesticides, air pollution, solvents, head trauma—and used simple examples to show why correlations must be tested experimentally. That point gave his pesticide work unusual credibility. Rather than stopping at observational data, he described the UCLA strategy of identifying candidate exposures in human populations and then moving into animal models to test biologic plausibility. His discussion of chlorpyrifos was the key example: epidemiologic association first, then mouse and zebrafish experiments showing impaired movement, dopamine-cell injury, alpha-synuclein accumulation, inflammatory microglial changes, and disrupted intracellular “garbage disposal” pathways. Bronstein’s bottom line was practical as well as scientific: every patient’s Parkinson’s may have a somewhat different causal mix, but many overlapping risk modifiers—exercise, diet, avoidance of toxic exposures—remain meaningful even after diagnosis. Bronstein is director of UCLA’s movement-disorders program, and UCLA describes his work as focused on Parkinson’s causes and therapy development, including zebrafish models.
The next lecture, from Dr. Chao Peng, moved the audience from epidemiology into molecular strategy. Peng’s subject was alpha-synuclein as the central “bad actor” in Parkinson’s pathology: a normally useful protein that can misfold, template further misfolding, amplify itself, and spread from cell to cell. His lab focus at UCLA is precisely this terrain—pathological alpha-synuclein, its conformational diversity, and ways to interrupt it.
Peng’s presentation was one of the symposium’s most forward-looking. He described three therapeutic choke points: blocking fibril formation, blocking cell-to-cell transmission, and blocking amplification of pathology inside recipient cells. The most striking part was his discussion of AI-assisted drug design. Standard small-molecule discovery, he argued, is poorly suited to the unusual geometry of alpha-synuclein fibrils, which are not ball-like proteins with ordinary pockets but layered fiber structures with repeated binding surfaces. His lab’s innovation was to redesign the computational approach so that the AI would favor repeating, stackable molecules capable of interacting with repeated fibril layers. He paired that with high-throughput experimental validation in neuron cultures exposed to pathologic alpha-synuclein. The conceptual message was that AI is not being used here as a buzzword, but as a way to attack a structural problem that ordinary medicinal chemistry handles badly.
He then broadened the strategy by discussing mathematical modeling of how pathology spreads across connected brain networks, and by showing how regional vulnerability can suggest new drug targets. Finally, he described work on post-translational modifications of soluble alpha-synuclein—small chemical “tags” that can either worsen or restrain pathologic conversion. This part of the symposium was especially important because it implied that treatment may not come from one blunt anti-synuclein approach, but from multiple more precise interventions tailored to different strains, conformations, or amplification states.
The third talk, from Dr. Lindsay De Biase, shifted the discussion from neurons to microglia, and in some ways deepened the entire symposium. UCLA describes De Biase’s work as centered on microglia and their role in neuroinflammation and aging-related vulnerability.
De Biase’s core argument was that Parkinson’s research has historically centered too narrowly on neurons, when in fact half the cells in the brain are non-neuronal, and microglia in particular may shape which neurons become vulnerable, when, and why. She explained microglia both as the brain’s “immune” cells and as active regulators of synapses, excitability, and tissue health. Her most memorable data concerned regional differences: in dopamine-rich midbrain regions, microglia appear to be fewer in number, less branched, and to have fewer lysosomes than in some neighboring regions. That matters because lysosomes are the cell’s degradative machinery. During aging, those lysosomes become overloaded with damaged proteins and lipids, microglia proliferate, inflammatory signaling rises, and local dopamine circuits perform worse. She then added a hopeful twist: microglia may also physically contact and protect dopamine neurons, and more such contact was associated with better behavioral performance in aging mice. De Biase’s talk gave the symposium one of its most important conceptual upgrades: Parkinson’s progression may depend not only on toxic proteins but on the state of the surrounding glial environment.
After the break, Dr. Kathryn (“Katy”) Cross brought the discussion into human physiology. UCLA describes her lab as studying gait impairment and human brain-circuit abnormalities in Parkinson’s disease, using tools such as virtual reality, EEG, motion capture, DBS recordings, and other neural measurements.
Cross’s lecture was excellent because it showed why walking is such a hard symptom to treat. Walking is not a single output; it is a constantly updated negotiation among rhythm, balance, visual input, cortical planning, and basal-ganglia “autopilot.” In Parkinson’s, especially in freezing of gait, that negotiation breaks down. Her group’s solution is to study walking while it is actually happening, not only in seated scans. She described mobile EEG, motion sensors, DBS recordings, eye tracking, and especially virtual reality designed to trigger freezing episodes in realistic but controlled settings. This was a very translational talk: the point is not merely to observe freezing, but to identify the exact brain signals that could someday guide adaptive stimulation or more targeted noninvasive neuromodulation. Cross’s contribution made clear that gait failure is not peripheral or secondary. It is one of the clearest demonstrations that Parkinson’s is a circuit disorder.
Next, Dr. Gal Bitan discussed the long arc of preclinical drug development. UCLA identifies Bitan’s lab with the development of molecular tweezers, especially the compound CLR01, as inhibitors of abnormal protein aggregation.
Bitan’s talk was perhaps the most concrete illustration of how a laboratory idea becomes a drug candidate. He walked the audience through the sequence: efficacy in test-tube aggregation assays, cell-culture toxicity rescue, zebrafish benefit, mouse-model benefit, toxicology, pharmacokinetics, and finally startup-company formation. His molecular tweezers do not eliminate alpha-synuclein; rather, they appear to redirect it away from the most toxic forms and to accumulate in lysosomes, where alpha-synuclein degradation is under pressure. This tied his talk elegantly back to De Biase’s lysosomal story. The audience could see, maybe more vividly than anywhere else in the symposium, how basic biophysics, animal modeling, and commercial translation fit together.
The symposium ended with Dr. Danielle Thordarson, a UCLA neurologist focused on movement disorders and Parkinson’s disease, who reviewed the current clinical-trials landscape. Her talk was valuable because it translated the morning’s science into near-term opportunities for patients. She emphasized that current Parkinson’s drugs remain mainly symptomatic, while the field is pushing toward disease modification.
She highlighted three especially important trial themes. First was prasinezumab, the anti-alpha-synuclein antibody now in Roche’s global Phase 3 PARAISO study for early-stage Parkinson’s disease. Second was NEU-411 in the Phase 2 NEULARK study for LRRK2-driven Parkinson’s disease, representing a more precision-based strategy. Third was bemdaneprocel, BlueRock’s stem-cell-derived cell therapy in the exPDite-2 study, a major effort to replace lost dopaminergic function. These trials are publicly listed as active investigational programs.
The larger achievement of the symposium was not that it offered a single answer. It did the opposite, and that was its strength. It showed Parkinson’s disease as a plural problem: partly proteinopathy, partly inflammatory disorder, partly aging disorder, partly circuit disorder, and partly an individualized biologic syndrome in which different patients may need different combinations of therapy. Across the talks, a common theme emerged: the future of Parkinson’s treatment will likely be layered. It may involve anti-synuclein strategies, microglial or lysosomal modulation, precision genetic therapies, circuit-guided stimulation, rehabilitation tools, and possibly restorative cell therapy. The symposium therefore succeeded not by promising a cure tomorrow, but by showing that UCLA is working across the entire path from molecule to mouse to mechanism to movement to medicine.
